Cost of Revenue in USD of LIXTE BIOTECHNOLOGY HOLDINGS, INC. from Q1 2022 to Q3 2023

Taxonomy & unit: us-gaap: USD
Description: The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary: LIXTE BIOTECHNOLOGY HOLDINGS, INC. quarterly Cost of Revenue history and change rate from Q1 2022 to Q3 2023.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Cost of Revenue for the quarter ending 30 Sep 2023 was $356,001, a 45% decline year-over-year.
Source SEC data: View on sec.gov

Cost of Revenue, Quarterly (USD)

Cost of Revenue, YoY Quarterly Change (%)

LIXTE BIOTECHNOLOGY HOLDINGS, INC. Quarterly Cost of Revenue (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2023		$356,001	-$287,956	-45%	01 Jul 2023	30 Sep 2023	10-Q	09 Nov 2023	2023	Q3
Q2 2023		$522,561	-$230,969	-31%	01 Apr 2023	30 Jun 2023	10-Q	09 Aug 2023	2023	Q2
Q1 2023		$519,480	-$46,442	-8.2%	01 Jan 2023	31 Mar 2023	10-Q	10 May 2023	2023	Q1
Q3 2022		$643,957			01 Jul 2022	30 Sep 2022	10-Q	09 Nov 2023	2023	Q3
Q2 2022		$753,530			01 Apr 2022	30 Jun 2022	10-Q	09 Aug 2023	2023	Q2
Q1 2022		$565,922			01 Jan 2022	31 Mar 2022	10-Q	10 May 2023	2023	Q1

* An asterisk sign (*) next to the value indicates that the value is likely invalid.